Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells

Journal of Neuroimmunology

Volumn 110, Issue 1-2, 2000, Pages 214-222

  Zipp, Frauke ^a   Wendling, Uwe ^a   Beyer, Martin ^a   Grieger, Ulrike ^a   Waiczies, Sonia ^a   Wagenknecht, Bettina ^b   Haas, Judith ^c   Weller, Michael ^b  

^a University Hospital   (Germany)

^b Jewish Hospital   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Autoimmunity; Human; MS; T lymphocytes

Indexed keywords

CASPASE; FAS ANTIGEN; GLUCOCORTICOID; PROTEIN BCL 2;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD95; APOPTOSIS; AUTOANTIGENS; CASPASES; CD4-POSITIVE T-LYMPHOCYTES; COUMARINS; DNA FRAGMENTATION; FLUORESCENT DYES; GENE EXPRESSION; GLUCOCORTICOIDS, SYNTHETIC; HUMAN; MEMBRANE GLYCOPROTEINS; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T;

EID: 0034597151     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00337-4     Document Type: Article

References (34)

1. Adams J.M., Cory S. The Bd-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
2. Bonetti B., Raine C.S. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 42:1997;74-84.
3. Boumpas D.T., Anastassiou E.D., Older S.A., Tsokos G.C., Nelson D.L., Balow J.E. Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J. Clin. Invest. 87:1991;1739-1747.
4. Buttgereit F., Wehling M., Burmester G.R. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited [comment]. Arthritis Rheum. 41:1998;761-767.
5. Cohen J.J., Duke R.C., Fadok V.A., Sellins K.S. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10:1992;267-293.
6. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., Lenardo M.J. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1994;1139-1143.
7. Garcia-Calvo M., Peterson E.P., Leiting B., Ruel R., Nicholson D.W., hornberry N.A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 49:1998;32608-32613.
8. Huang S.-T.J., Cidlowski J.A. Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2. FASEB J. 13:1999;467-476.
9. Malipiero U., Frei K., Spanaus K.-S., Agresti C., Lassmann H., Hahne M., Tschopp J., Eugster H.-P., Fontana A. Myelin oligodendrocyte glycoprotein-induced encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. Eur. J. Immunol. 27:1997;3151-3160.
10. Moreno M.B., Memon S.A., Zacharchuk C.M. Apoptosis signaling pathways in normal T cells. Differential Activity of bcl-2 and IL-1b-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. J. Immunol. 157:1996;3845-3849.
11. Naumann U., Durka S., Weller M. Dexamethasone-mediated protection from drug toxicity linked to p21WAF/CIP1 protein accumulation. Oncogene. 17:1998;1567-1575.
12. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
13. Perandones C.E., Illera V.A., Peckham D., Stunz L.L., Ashman R.F. Regulation of apoptosis in vitro in mature murine spleen T cells. J. Immunol. 151:1993;3521-3529.
14. Rothenberg E.V. The development of functionally responsive T cells. Adv. Immunol. 51:1992;85-214.
15. Roy M., Deveraux Q.L., Takahashi R., lvesen G.S., ed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:1997;6914-6925.
16. Sabelko-Downes K.A., Cross A.H., Russell J.H. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189:1999;1195-1205.
17. Sabelko K.A., Kelly K.A., Nahm M.H., Cross A.H., Russell J.H. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:1997;3096-3099.
18. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687.
19. Scaffidi C., Medema J.P., Krammer P.H., Peter M.E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and capase-8/b. J. Biol. Chem. 272:1997;26953-26958.
20. Schmied M., Breitschopf H., Gold R., Zischler H., Rothe G., Wekerle H., Lassmann H. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis: Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 143:1993;446-452.
21. Tamura A., Katsumata M., Greene M.I., Yui K. Inhibition of apoptosis and augmentation of lymphoproliferation in bcl-2 transgenic Fas/Fas ligand-defective mice. J. Cell. Immunol. 168:1996;220-228.
22. Trauth B.C., Klas C., Peters A.M.J., Matzku S., Müller P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-305.
23. Tuosto L., Cundari E., Montani M.S., Piccolella E. Analysis of susceptibility of mature human T lymphocytes to dexamethasone-induced apoptosis. Eur. J. Immunol. 24:1994;1061-1065.
24. Waldner H., Sobel R.A., Howard E., Kuchroo V.K. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159:1997;3100-3103.
25. Weller M., Constam D.B., Malipiero U., Fontana A. Transforming growth factor-b2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur. J. Immunol. 24:1994;1293-1300.
26. Weller M., Malipiero U., Rensing-Ehl A., Barr P.J., Fontana A. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55:1995;2936-2944.
27. Wyllie A.H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 284:1980;555-556.
28. Yang Y., Mercep M., Ware C.F., Ashwell J.D. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J. Exp. Med. 181:1995;1673-1682.
29. Zacharchuk C.M., Mercep M., Chakraborti P.K., Simons S.S. Jr., Ashwell J. Programmed T lymphocyte death. Cell activation- and steroid- induced pathways are mutually antagonistic. J. Immunol. 145:1990;4037-4045.
30. Zhou T., Song L., Yang P., Wang Z., Lui D., Jope R.S. Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat. Med. 5:1999;42-48.
31. Zipp F., Martin R., Lichtenfels R., Roth W., Dichgans J., Krammer P.H., Weller M. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J. Immunol. 159:1997;2108-2115.
32. Zipp F., Weller M., Calabresi P.A., Frank J.A., Bash C.N., Dichgans J., McFarland H., Martin R. Increased serum levels of soluble CD95 (APO1/Fas) in relapsing remitting multiple sclerosis. Ann. Neurol. 43:1998;116-120.
33. Zipp F., Otzelberger K., Dichgans J., Martin R., Weller M. Serum CD95 of multiple sclerosis patients protects from CD95- mediated apoptosis. J. Neuroimmunol. 86:1998;151-154.
34. Zipp F., Krammer P.H., Weller M. Immune (dys)regulation in multiple sclerosis: role of the CD95/CD95 ligand system. Immunol. Today. 20:1999;550-554.